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PERSONALIZED TREATMENT OF ADULT DEPRESSION:
MEDICATION, PSYCHOTHERAPY, OR BOTH? A
SYSTEMATIC REVIEW
Pim Cuijpers, Ph.D.,1,2∗ Charles F. Reynolds III, Ph.D., M.D.,3 Tara Donker, Ph.D.,1,2 Juan Li, Ph.D.,4
Gerhard Andersson, Ph.D.,5,6 and Aartjan Beekman, Ph.D., M.D.7
Background: Personalized medicine aims to identify which characteristics of an
individual predict the outcome of a specific treatment, in order to get a bet-
ter match between the individual and the treatment received. We conducted a
systematic review and meta-analysis of randomized trials comparing two treat-
ments directly in a group of patients with a specific characteristic. Methods:
We searched relevant studies from bibliographical databases and included tri-
als comparing (1) medication with psychotherapy, (2) medication with combined
treatment, and (3) psychotherapy with combined treatment, in specific target
groups (a) with a predefined sociodemographic characteristic, (b) a specific type
of depression, (c) a comorbid mental or somatic disorder, or (d) from a specific
setting (outpatients, primary care). Results: We included 52 studies with 4,734
depressed patients. In these studies, 20 characteristics of the target groups were
examined. The results showed that medication is probably the best treatment for
dysthymia, and combined treatments are more effective in depressed outpatients,
as well as in depressed older adults. However, in order to examine the 20 char-
acteristics in the three categories of comparisons, 254 studies would be needed
for having sufficient statistical power to show an effect size of g = 0.5. Cur-
rently, only 20.1% of these studies have been conducted. Conclusions: Although
a considerable number of studies have compared medication, psychotherapy, and
combined treatments, and some preliminary results are useful for deciding which
treatment is best for which patient, the development of personalized treatment
of depression has only just begun. Depression and Anxiety 00:1–10, 2012.
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INTRODUCTION
It is well established that antidepressive medication, as
well as psychotherapies have signiﬁcant effects on adult
depressive disorders,[1–4] that both are about equally
effective,[5–7] and that combined treatments are slightly
more effective than either psychotherapy alone,[8–10] or
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medication alone.[11,12] However, it is also clear that
many patients do not respond to these treatments,[13,14]
and it is largely unknown which individual patient will
respond to which medication or psychotherapy.[15,16]
Personalizedmedicine aims at identifying which char-
acteristics of an individual predict the outcome of a spe-
ciﬁc treatment in order to get a bettermatch between the
individual and treatment received.[17] These character-
istics may include sociodemographic characteristics and
clinical characteristics of the depressive disorder, as well
as biological markers, such as neuroimaging or genetic
variation.[17] The development of personalized treat-
ments is considered bymany to be one of themajor chal-
lenges for health care research in the next decades.[18–20]
One good design to examine whether one treatment
is better than another treatment for a patient with a
speciﬁc characteristic would be a randomized controlled
trial comparing these two treatments directly in a group
of patients with that characteristic.[17] For example, if we
want to examine whether a new antidepressant is more
effective than existing antidepressants in older patients,
a randomized trial directly comparing the new antide-
pressant with an existing antidepressant in a group of
older patients would be the optimal design. A design
that does not include a direct comparison between two
treatments, but only, for example, a comparison between
an active treatment and a control condition, does not an-
swer the question whether one treatment is better than
another for this speciﬁc group of patients. This type of
research is therefore not helpful in developing person-
alized treatments.[17]
Another design that may be helpful in developing per-
sonalized treatments is a direct comparison between two
treatments in an unselected group of patients with a de-
pressive disorder, with analyses examining whether one
treatment was more effective than the other in prede-
ﬁned subgroups of patients. In our example that would
mean that we would compare two treatments in a large
group of depressed patients, and examine whether older
adults beneﬁt more from one treatment than from the
other, comparedwith younger adults. In such trials, how-
ever, it is important to deﬁne in advance which charac-
teristics will be examined, in order to avoid capitalization
on chance and a focus on post hoc analyses. Until now,
hardly any of such trialswith predeﬁnedmoderators have
been conducted,[15,16] and we will therefore not review
these studies here.
In the past few decades, several dozens of random-
ized trials have directly compared antidepressive med-
ication, psychotherapy, and combined treatments with
each other.Many of these comparative studies have been
conducted in speciﬁc subgroups of patients, such as dys-
thymic patients and patients with postpartum depres-
sion, but also in older adults, and in patients with gen-
eral medical disorders. These studies can be used to
examine whether one treatment is better than another
in these speciﬁc target groups, and can contribute to
the development of personalized treatments for adult
depression.
We decided to conduct a systematic review of these
studies. Such a review can give a general indication of
where we are in the development of personalized treat-
ments of adult depression. Because we expected that
many studies would not have sufﬁcient statistical power
to ﬁnd signiﬁcant differences between treatments in a
speciﬁc subgroup of patients, we also calculated how
many studies are needed to ﬁnd clinically relevant com-
parative effects in such subgroups, and how many more
should be conducted in order to be sure that we have not
missed any relevant differences.
METHOD
IDENTIFICATION AND SELECTION OF STUDIES
A database of 1,237 papers on the psychological treatment of
depression was used. This database has been described in de-
tail elsewhere,[21] and used in a series of earlier published meta-
analyses (www.evidencebasedpsychotherapies.org), including several
meta-analyses comparing psychotherapy, antidepressive medication,
and combined treatments.[6,7,10,12] The database is continuously
updated and was developed through a comprehensive literature
search (from 1966 to January 2011) in which 12,368 abstracts in
Pubmed (3,077 abstracts), PsycInfo (2,860), Embase (3,811), and
the Cochrane Central Register of Controlled Trials (2,885) were
examined. These abstracts were identiﬁed by combining terms in-
dicative of psychological treatment and depression (both MeSH
terms and text words). For this database, the primary studies
from 42 meta-analyses of psychological treatment for depression
were also checked to ensure that no published studies had been
missed (http://www.evidencebasedpsychotherapies.org). For the cur-
rent study, the full texts of these 1,237 papers were examined. The ref-
erence lists of earlier review andmeta-analyses comparing medication,
psychotherapy, and combined treatments were also examined,[5–12] as
well as the references of the included primary studies.
We included randomized trials on short-term or acute treatment
in which the effects of antidepressant medication were directly com-
pared with the effects of psychotherapy or with a combined treatment,
as well as randomized trials in which psychotherapy was compared
with a combined treatment. We only included studies in which partic-
ipants had an established depressive disorder according to a diagnostic
interview. From these trials we selected those in which one of the
comparisons (pharmacotherapy versus psychotherapy, pharmacother-
apy versus combined, psychotherapy versus combined) was examined
in a speciﬁc target group with (a) a predeﬁned sociodemographic char-
acteristic (such as older adults or minority groups), (b) with a speciﬁc
type of depression (such as dysthymia, chronic depression, or post-
natal depression), (c) depression and a comorbid (mental or somatic)
disorder, or (d) a target group from a speciﬁc setting (outpatients, pri-
mary care). Target groups from outpatient and primary care settings
were considered to represent speciﬁc categories of depressed patients
withdistinctive characteristics. Studies inwhichpatientswere recruited
from the community were not included because this does not represent
a speciﬁc or deﬁnable patient group.We excluded studies on inpatients
and on children and adolescents below 18 years of age.
QUALITY ASSESSMENT
We assessed the quality of the studies according to four basic
criteria suggested by the Cochrane Handbook for Systematic Reviews
of Interventions[22]: adequate sequence generation (the randomiza-
tion scheme was generated correctly), allocation to conditions by
an independent (third) party, blinding of assessors of outcomes, and
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completeness of follow-up data. Data extraction was conducted by two
independent researchers.
META-ANALYSES
We distinguished three types of comparisons: (1) medication versus
psychotherapy, (2) medication only versus combined medication plus
psychotherapy, and (3) psychotherapy only versus combined medica-
tion plus psychotherapy. Analyses were conducted separately for each
of these three types of comparisons.
For each comparison we calculated the effect size indicating
the difference between the two treatments at posttest, adjusted for
small sample bias (Hedges’ g).[23] Effect sizes were calculated by
subtracting (at posttest) the average score of the ﬁrst treatment from
the average score of the second treatment, and dividing the result by
the pooled standard deviations of the two groups. We only used those
instruments that explicitly measured symptoms of depression, such as
the Beck Depression Inventory,[24] or the Hamilton Rating Scale for
Depression (HRSD).[25] If more than one depression measure was
used, the mean of the effect sizes was calculated, so that each study
provided only one effect.
Within each of the three categories of comparisons, we calculated
effect sizes for each study in which a speciﬁc target group was exam-
ined (with a speciﬁc sociodemographic characteristic, a speciﬁc type
of depression; a speciﬁc comorbid disorder; or a speciﬁc setting). If
more outcomes for each such comparison were available, we used the
computer programComprehensiveMeta-Analysis (version 2.2.021) to
calculate pooled mean effect sizes. As we expected considerable het-
erogeneity, we decided to calculate mean effect sizes using a random
effects model. In all analyses we calculated the I2-statistic an indicator
of heterogeneity in percentages (25% indicates low, 50% moderate,
and 75% high heterogeneity).[26] We also calculated the Q-statistic,
but only report whether this was signiﬁcant or not.
POWER CALCULATIONS
Because we examined three groups of comparisons (medication
versus psychotherapy, medication versus combined treatment, psy-
chotherapy versus combined treatment), and wanted to examine sep-
arate effect sizes for speciﬁc target groups (with a speciﬁc sociodemo-
graphic characteristic, type of depression, comorbid disorder, setting),
we expected that for most comparisons insufﬁcient statistical power
was available to ﬁnd clinically relevant effect sizes. Therefore, we con-
ducted a power calculation for each comparison we examined.
For each comparison, we calculated how many studies are needed
to have sufﬁcient statistical power for ﬁnding an effect size of g =
0.5. Effect sizes of 0.5 have been deﬁned as a threshold for clinical
signiﬁcance in several studies.[27,28] Hedges’ g indicates the difference
between two treatments at posttest in terms of standard deviations,
adjusted for small sample bias. An effect size of g = 0.5 corresponds
with a numbers-needed-to-be-treated (NNT) of 3.62.[29]
For each comparison, we calculated the mean number of partici-
pants in each treatment condition. Thenwe calculated howmany stud-
ies with this number of participants would be needed to ﬁnd an effect
size of g = 0.5. The power calculations were conducted according to
the procedures suggested by Bohrenstein et al.[30] In these calculations
we conservatively assumed a medium level of between-study variance,
τ2, a statistical power of 0.80, and a signiﬁcance level, alpha, of .05.
Because we calculated the number of studies needed to show sig-
niﬁcant effect sizes of 0.5, we were also able to calculate what percent
of the studies needed to ﬁnd these effect sizes, have been conducted.
This gives an indication howmany studies still have to be conducted in
order to ﬁnd signiﬁcant effect sizes of g = 0.5 for each of the examined
characteristics.
RESULTS
SELECTION AND INCLUSION OF STUDIES
Having examined 12,368 abstracts (9,634 after re-
moval of duplicates), we retrieved 1,237 full-text papers
for further consideration, of which 1,185 were excluded.
Fifty-two trials met inclusion criteria (Fig. 1).
CHARACTERISTICS OF INCLUDED STUDIES
Selected characteristics of the included studies ap-
pear in Appendix A, and references are given in Ap-
pendix S1 (available as supplementary data online).
Depressed patients (4,734) participated in these stud-
ies (1,720 in psychotherapy; 1,925 in pharmacother-
apy; and 1,089 in combined conditions). These 52
studies contained 33 direct comparisons between psy-
chotherapy and pharmacotherapy, 29 comparisons be-
tween pharmacotherapy and combined treatment, and
14 comparisons between psychotherapy and combined
treatment.
In the included studies, 20 characteristics of the target
groups were examined. Six of these were examined in
each of the three categories of comparisons (psychother-
apy versus medication, medication versus combined,
psychotherapy versus combined: dysthymia, chronic
depression, older adults, stroke patients, primary care,
outpatients), one characteristic was examined in two
categories (postnatal depression), and the remaining
13 characteristics were examined in one of the three
categories (Table 1).
QUALITY ASSESSMENT
The quality of the studies varied. Nineteen studies
reported an adequate sequence generation, whereas the
other 33 did not report a sequence generation method.
Figure 1. Flowchart of inclusion of studies.
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TABLE 1. Comparative studies of psychotherapy, pharmacotherapy, and combined treatments adult depression for
specific target populations
Studies needed to show effect
size g = 0.5
ka G 95% CI N/condb ka Percentage realized
Pharmacotherapy or psychotherapy?c
Type of depression
• Dysthymia 6 −0.28 −0.53∼−0.04* 43 3 100%
• Atypical depression 1 −0.22 −0.68∼0.24 36 3 33.3%
• Chronic depression 1 −0,04 −0.23∼0.15 218 1 100%
• Postnatal depression 1 −0.48 −0.75∼−0.22*** 109 1 100%
• Minor depression 2 −0.09 −0.44∼0.26 39 3 66.7%
Sociodemographic
• Older adults 3 0.05 −0.16∼0.25 62 2 100%
• Poor minority women 1 −0,24 −0.53∼0.05 89 2 50.0%
• infertile women 1 −0.94 −1.47∼−0.41** 30 4 25.5%
• Living with a partnere 1 0.00 −0.44∼0.44 39 3 37.5%
Comorbid conditions
• Multiple sclerosis 2 −0.18 −0.70∼0.34 18 6 33.3%
• Stroke patients 1 0.25 −0.30∼0.79 26 5 20.0%
Setting
• Primary care 10 −0.01 −0.14∼0.11 48 3 100%
• Outpatients 11 0.08 −0.16∼0.32 101 2 100%
Pharmacotherapy or combined?d
Type of depression
• Dysthymiab 4 0.06 −0.20∼0.33 46 3 100%
• Chronic depression 1 0.54 0.35∼0.73*** 221 1 100%
• Postnatal depression 1 −0.03 −0.71∼0.66 16 7 14.3%
• Treatment resistant 1 1.82 0.21∼3.43* 13 9 11.1
• High cognitive dysfunction 1 1.31 0.32∼2.29** 9 12 8.3
• Bereavement related 1 0.30 −0.42∼1.01 21 6 16.7%
Sociodemographic
• Older adults 3 0.46 0.12∼0.80** 21 6 50.0%
Comorbid conditions
• Coronary heart disease 1 0.06 −0.27∼0.39 71 2 50.0%
• Stroke patients 1 −0.12 −0.68∼0.45 24 5 20.0%
• OCD 1 0.36 −0.17∼0.89 27 4 25.0%
• Borderline 1 0.90 0.19∼1.61* 16 7 14.3%
• Personality disorder 1 0.34 −0.36∼1.05 16 7 14.3%
Setting
• Primary care 2 0.75 −0.97∼2.47 24 5 40.0%
• Outpatients 15 0.54 0.35∼0.74*** 28 4 100%
Psychotherapy or combined?d
Type of depression
• Dysthymiab 2 0.41 −0.17∼0.98 62 2 100%
• Chronic depression 1 0.54 0.35∼0.73*** 221 1 100%
Sociodemographic
• Older adults 1 0.08 −0.40∼0.55 34 4 25.0%
Comorbid conditions
• Stroke patients 1 −0.29 −0.84∼0.26 25 5 20.0%
Setting
• Primary care 2 0.31 −0.01∼0.63 40 3 66.7%
• Outpatients 9 0.40 0.13∼0.67** 44 3 100%
ak indicates the number of studies.
bN/cond indicates the mean number of patients per research condition.
cA positive effect size indicates a superior effect of the psychological treatment.
dA positive effect size indicates that combined treatment is more effective.
eThis study examined couple therapy and therefore required the presence of a partner.
* p < 0.05; ** p < 0.01; *** p < 0.001.
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TABLE 2. Meta-analyses of specific subsets of studies on treatments for adult depression with at least three
comparisons and sufficient statistical power
k g 95% CI Z I2
Pharmacotherapy or psychotherapy?
• Dysthymia 6 −0.28 −0.53∼−0.04 − 2.29* 32.96
• Older adults 3 0.05 −0.16∼0.25 0.46 0
• Primary care 10 −0.01 −0.14∼0.11 − 0.23 0
• Outpatients: all studies 11 0.08 −0.16∼0.32 0.65 68.24***
o Two outliers excluded 9 −0.09 −0.23∼0.04 − 1.32 11.24
Pharmacotherapy or combined?
• Dysthymiab 4 0.06 −0.20∼0.33 0.48 15.70
• Older adults 3 0.46 0.12∼0.80 2.66** 0
• Outpatients 15 0.54 0.35∼0.74 5.51*** 34.36
o Two outliers removed 13 0.47 0.32∼0.62 6.05*** 2.36
Psychotherapy or combined?
• Outpatients 9 0.44 0.19∼0.69 3.40** 45.36
o One outlier removed 8 0.37 0.18∼0.55 3.89*** 9.11
* p < 0.05; ** p < 0.01; *** p < 0.001.
Seventeen studies reported allocation to conditions by an
independent (third) party. Forty studies reported using
blinded outcome assessors, 12 did not report blinding
of assessors or used self-report outcome measures. In 32
studies, intent-to-treat analyses (completeness of follow-
up data) were conducted. Eleven studies (21%) met all
quality criteria.
PSYCHOTHERAPY OR PHARMACOTHERAPY?
We identiﬁed 13 patient characteristics that were ex-
amined in comparative outcome studies of medication
and psychotherapy (Table 1). We found that medica-
tion was signiﬁcantly more effective than psychother-
apy in patients with dysthymia (g = −0.28; 95% CI:
−0.53∼0.04), in patients with postnatal depression, and
depressed infertile women.However, the results in post-
natal depression and infertile womenwere each based on
only one study.
We found no signiﬁcant difference between the ef-
fects of medication and psychotherapy in primary care
patients and outpatients, chronic depression and older
adults, while there was sufﬁcient statistical power. For all
other characteristics we found no signiﬁcant difference
between medication and psychotherapy, but the stud-
ies of these characteristic also had insufﬁcient statistical
power to ﬁnd signiﬁcant effects.
Overall, the power calculations indicated that we
would need 38 studies to show that the 13 character-
istics had a differential effect size of g = 0.5. Only 21
studies (55.3%) have been conducted.
For the groups of studies with at least three com-
parisons, we conducted additional analyses (Table 2).
We found no indication for signiﬁcant heterogeneity
in studies on dysthymia, older adults, and primary care.
We did ﬁnd signiﬁcant heterogeneity in studies in out-
patients. After exclusion of two possible outliers (with
effect sizes outside the 95% conﬁdence interval of the
meaneffect size), heterogeneitywas reduced to a very low
TABLE 3. Preliminary advice on personalized treatment for adult depression
Summary of Differential kb First choice
outcomesa effect size of treatment
Dysthymia PHA > PSY − 0.28* 6 PHA
PHA = COMB 0.06 4
PSY = COMB 0.41 2
Older adults PHA = PSY 0.05 3 COMB
COMB > PHA 0.46** 3
Primary care PHA = PSY − 0.01 10 PSY or PHA
Outpatients PHA = PSY 0.08 11 COMB
COMB > PHA 0.54*** 15
COMB > PSY 0.44* 9
PHA, pharmacotherapy; PSY, psychotherapy; COMB, combined treatment.
a“>” indicates that the ﬁrst treatment is more effective than the second treatment; “ = ” indicates that no signiﬁcant difference was found between
the two treatments, while sufﬁcient statistical power was available.
bk, number of studies.
* p < 0.05; ** p < 0.01; *** p < 0.001.
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level and was no longer signiﬁcant. One of the outliers
was conducted in a non-Western country,[31] whereas
the other one was a very small, older, and low-quality
study.[32]
PHARMACOTHERAPY OR COMBINED
TREATMENT?
We identiﬁed 14 patients characteristics that were
examined in comparative outcome studies of medica-
tion and combined treatment. We found that combined
treatment was signiﬁcantly more effective than medica-
tion alone in outpatients (g = 0.54; 95%CI: 0.35∼0.74),
in older patients, and in chronically depressed patients,
treatment resistant depression, in depressed patients
with impaired cognitive function, and patients with a
comorbid borderline personality disorder. However, the
results in older adults, chronic depression, cognitive im-
pairment, and comorbid personality disorder were each
based on only one study. Furthermore, the studies in
high cognitive dysfunction and comorbid personality
disorder did not have sufﬁcient power to ﬁnd signiﬁcant
effects.
No signiﬁcant difference was found between medica-
tion and combined treatment in dysthymic patients, al-
though the four studies examining this comparison had
sufﬁcient power. For all other characteristics we found
no signiﬁcant difference between medication and psy-
chotherapy, and the studies for each characteristic had
insufﬁcient statistical power.
The power calculations indicated that we would need
78 studies to show that the 14 characteristics had a dif-
ferential effect size of g = 0.5. However, only 22 studies
(28.2%) have been conducted.
For the groups of studies with at least three compar-
isons, we again examined the level and if needed possi-
ble sources of heterogeneity. The three studies in older
adults indicated that combined treatment was more ef-
fective than pharmacotherapy alone, although this did
not reach the level of clinical signiﬁcance of g = 0.5. As
can be seen in Table 2, heterogeneity was not signiﬁcant
in all three groups of studies. Although heterogeneity
was low in studies in dysthymia and older adults, it was
low to moderate in studies among outpatients. After re-
moval of two comparisons from one small, old, and low-
quality study,[32] with extremely high effect sizes in favor
of combined treatment, the mean effect size was some-
what smaller (g = 0.47), but heterogeneity was reduced
to almost zero (I2 = 2.36%).
PSYCHOTHERAPY OR COMBINED TREATMENT?
We found six patients characteristics that were ex-
amined in comparative outcome studies of psychother-
apy and combined treatment. Combined treatment was
signiﬁcantly more effective than psychotherapy alone
in outpatients (g = 0.48; 95% CI: 0.34∼0.63), and
in chronic depression, although this last outcome was
based on only one study. Both outcomes had sufﬁ-
cient power. None of the other examined characteris-
tics was associated with a larger effect size for either
treatment, nor did these studies have sufﬁcient statistical
power.
Overall, the power calculations indicated that we
would need 18 studies to show that the six character-
istics had a differential effect size of g = 0.5. However,
only 10 studies (55.6%) have been conducted.
The only group of studies with three comparisons was
aimed at depressed outpatients. The effect size indicat-
ing the difference between psychotherapy and combined
treatment was 0.40 (95%CI: 0.13∼0.67). Heterogeneity
was moderately high and signiﬁcant (P < .05), but after
removal of one outlier,[33] heterogeneity became small
and non-signiﬁcant.
OVERALL RESULTS
If we would want to examine the 20 characteristics in
each of the three categories of comparisons (resulting
in 60 comparisons), we would need 254 studies with a
comparable N as the studies that have been conducted
until now, in order to have sufﬁcient statistical power
for an effect size of g = 0.5. At this moment, only 51 of
these studies have been conducted (20.1%; this number
is lower than the actual number of available studies be-
cause some characteristics have been examined in more
studies than would be needed from the point of view of
statistical power).
Based on the results of this review, it would be pos-
sible to make a preliminary recommendation for four
of the characteristics (Table 3). In patients with dys-
thymia, medication is signiﬁcantly more effective than
psychotherapy, whereas combined treatment is not sig-
niﬁcantly more effective than either medication or psy-
chotherapy alone. Therefore, medication seems to be
the best ﬁrst-line treatment in these patients, at least in
the short term. In older adults, no signiﬁcant difference
between medication and psychotherapy was found, but
combined treatment is signiﬁcantly better than medi-
cation alone. Combined treatment seems to be the best
treatment option in this group. In outpatients, combined
treatment is signiﬁcantly more effective than either psy-
chotherapy alone or medication alone, and seems to be
the best treatment for this group. However, the only
effect size that was larger than g = 0.5 (indicating clini-
cal signiﬁcance) was the effect size indicating that com-
bined treatment is more effective than pharmacotherapy
alone in outpatients. In primary care patients, only med-
ication and psychotherapy have been compared directly
with each other and no signiﬁcant difference between
the two was found. Insufﬁcient research on combined
treatments is available, so no further advice can be given
for this group of patients.
DISCUSSION
We reviewed studies in which psychotherapy, medi-
cation, and combined treatment were directly compared
in depressed populations with speciﬁc characteristics,
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because these studies are one of the best sources of
knowledge for personalized treatments. We identiﬁed
52 of such studies, examining 20 speciﬁc patient
characteristics. Although this may seem a considerable
number of studies, we found that many more studies
are needed. If we want to have sufﬁcient statistical
power to ﬁnd clinically relevant differential effect sizes
of 0.5,[27] we would need 254 studies (with about
23,000 patients) of which only 51 have been conducted
(20.1%).
This is onlywhat is needed to developpersonalized de-
cisions about three types of treatment. If we would want
to differentiate between the many available antidepres-
sant medications and psychotherapies, and all possible
combinations (in combined treatments), we will proba-
bly need many thousands of studies, only a fraction of
which have now been conducted, and millions of partic-
ipating patients. This problem is multiplied if we focus
on other characteristics that have not yet been exam-
ined in trials until now, such as biomarkers. And if we
reallywant to developpersonalized treatments of depres-
sion, we should not only look at individual characteris-
tics of patients and treatments, but also on combinations
of characteristics, such as older adults with atypical de-
pression and a speciﬁc biomarker. Furthermore, we may
want to look at other outcomes, such as side effects of
medications, long-term outcomes, patient preferences,
and prediction of treatment dropout. And we could also
choose for a more precise effect size of g = 0.3 or even
0.2. This would require an almost endless number of
randomized trials and even more patients who are will-
ing to participate in such trials. There is no doubt that
the path toward personalized treatments is a long one,
requiring considerable resources.
On the other hand, the number of studies can be re-
duced considerably if we also use other research designs
instead of randomized trials comparing different treat-
ments in speciﬁc target populations. As indicated ear-
lier, another design that may be helpful in developing
personalized treatments is a direct comparison between
two treatments in an unselected group of patients with
a depressive disorder, with analyses examining whether
one treatment was more effective than the other in spe-
ciﬁc predeﬁned subgroups of patients.[17] Several of such
studies have, for example, examined the severity of de-
pression in comparative outcome studies of medication
and psychotherapy,[34,35] as has been discussed in a re-
cent thoughtful discussion of personalized treatments
for depression.[17] However, such designs do not solve
the problem of statistical power, because in such a trial
still sufﬁcient patients should be included with the spe-
ciﬁc characteristic we want to examine. And as indicated
earlier, in order to avoid capitalization on chance, we
need to deﬁne in advance what the patient characteris-
tics are that we want to examine. Otherwise we will only
be able to conduct post hoc analyses, and these would
require replication in a new trial. Until now, hardly
any of such trials with predeﬁned moderators have been
conducted.[16]
Currently, new methodological approaches are de-
veloped to examine moderators of outcome, such as
Bayesian approaches and decision tree analyses.[36] Al-
though such studies do not solve the problem of statisti-
cal power and capitalization on chance, they may prove
to be a considerable help in developing relevant hypothe-
ses for personalized treatments. A recent report of the
Institute of Medicine on comparative outcome research,
comparisons of the effectiveness of pharmacologic treat-
ment and behavioral interventions in managing major
depressive disorders are described as one of the prior-
ities for further research.[37] This will certainly lead to
more sophisticated and economical methodologies for
developing personalized treatments.
The trials that have been conducted until now may
be only the beginning for personalized treatment of de-
pression, but the results are already important from a
clinical point of view. Medications seem to be the best
treatment for dysthymia and combined treatments are
clearly more effective in depressed outpatients, as well as
in depressed older adults. These ﬁndings have to be con-
sidered with caution, because they are still about broad
categories of treatment and not about speciﬁc medica-
tions or psychotherapies. However, this does seem to
give a general direction for these target groups, which
can be worked out in further research.
The results of this systematic review should be consid-
ered in light of its limitations. Several of these have been
described already. The studies examined in this review
are not the only type of studies that results in relevant
information about speciﬁc treatments for speciﬁc target
populations. However, the trials we reviewed do result
in the best available evidence. And although the number
of studies was relatively large, many more are needed
before we actually are capable of personalizing treat-
ments for adult depression. A problem with the current
set of studies was that the quality was not optimal, and
only a selected number of potentially relevant modera-
tors were examined.We also only focused on short-term
outcomes, whereas longer term outcomes may be more
relevant from a clinical point of view.
Personalized treatment of depression is one of the
most important challenges for mental health researchers
in the next decades. A large body of research has resulted
in useful preliminary data, but much more research is
needed before we can actually give personalized advice
to patients. There is no doubt, however, that the de-
velopment of personalized treatment for depression has
begun.
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APPENDIX A. Selected characteristics of studies comparing psychotherapy with
medication, psychotherapy with combined treatment, or medication with
combined treatment in adults with depressive disorders
Studies Patient characteristic Psychotherapy N Nsess I/G Medication N Combined
Barrett (2001) Dysthymia/minor
depression
PST 37 6 Ind Paroxetine 35 −
Beck (1985) Outpatients CBT 14 20 Ind − Amitriptyline + CBT
Bedi (2000) Primary care Counseling 39 6 Ind AD protocol 44 −
Bellino (2006) Borderline patients − 24 Ind Fluoxetine 16 IPT + ﬂuoxetine
Blackburn (1997) Outpatients CBT 24 16 Ind AD of choice 23 −
Blom (2007) Outpatients − 12 Ind Nefazodone 30 IPT + nefazodone
Browne (2002) Dysthymia w/wo
MDD
IPT 83 10 Ind − IPT + sertraline
Burnand (2002) Outpatients − 10 Ind Clomipramine 38 Psychodynamic + clomip.
De Jonghe (2001) Outpatients − 16 Ind Protocol 84 Psychodynamic + protocol
De Mello (2001) Outpatients − 16 Ind Moclobemide 13 IPT + moclobemide
Dekker (2008) Outpatients Psychodynamic 58 16 Ind Venlafaxine 42 −
Dozois (2009) Outpatients − 15 Ind Protocol 21 CBT + protocol
Dunner (1996) Dysthymia CBT 10 16 Ind Fluoxetine 12 −
Faramarzi (2008) Infertile women;
outpatients
CBT 29 10 Grp Fluoxetine 30 −
Finkenzeller (2009) Stroke patients IPT 27 12 Grp Sertraline 24 IPT + sertraline
Frank (2010) Outpatients IPT 160 12 Ind Escitalopram 158 −
Hautzinger (1996) Outpatients CBT 33 24 Ind − CBT + Amitriptyline
Hellerstein (2001) Dysthymia;
outpatients
− 16 Grp Fluoxetine 20 Group ther + ﬂuoxetine
Hollon (1992) Outpatients CBT 25 20 Ind Imipramine 57 CBT + imipramine
Jarrett (1999) Atypical depression CBT 36 20 Ind Phenelzine 36 −
Keller (2000) Chronic depression;
outpatients
CBASP 216 18 Ind Nefazodone 220 CBASP + nefazodone
Leff (2000) Living with a partner Couple therapy 37 16 Ind Desipramine a 40 −
Lesperance (2007) Coronary artery
disease
− 12 Ind Citalopram 75 IPT + citalopram
Lynch (2007) Personality disorder;
elderly
− 28 Grp Protocol 12 DBT + protocol
Lynch (2003) Elderly − 56 I + G Protocol 9 DBT + protocol
Macaskil (1996) High cognitive dysf.;
outpatients
− 30 Ind Lofepramine 9 RET + lofepramine
Maina (2010) OCD patients − 13 Ind Fluvox. or sertral. 29 Dynamic + pharmacother.
Maldonado (1982) Outpatients CBT 8 10 Ind TCA (ns) 8 −
Maldonado (1984) Outpatients − 8 10 Ind TCA (ns) 8 CBT + TCA
SST + TCA
Markowitz (2005) Dysthymia IPT 23 17 Ind Sertraline 24 IPT + sertraline
Supportive 26 17 Ind
Martin (2001) Primary care IPT 13 16 Ind Venlafaxine 15 −
Miranda (2003) Impoverished
minority women
CBT 90 8 I + G Paroxetine a 88 −
Misri (2004) Postpartum
depression
12 Ind Paroxetine 14 CBT + paroxetine
Mohr (2001) MS patients CBT 20 16 I Sertraline 15 −
Supportive 19 16 G
Murphy (1984) Outpatients CBT 24 20 Ind Nortriptyline 24 CBT + nortriptyline
Mynors-Wallis (1995) Primary care PST 29 6 Ind Amitriptyline 27 −
Mynors-Wallis (2000) Primary care PST—GP 39 6 Ind Fluvox. or parox. 36 PST-GP + pharmacother.
PST—nurse 41 6 Ind
Ravindran (1999) Dysthymia − 12 Grp Sertraline 22 CBT + sertraline
Reynolds (1999) Bereavement-related
depression
− 16 Ind Nortriptyline 25 IPT + nortriptyline
Rush (1977) Outpatients CBT 19 20 Ind Imipramine 22 −
Rush (1981) Outpatients CBT 8 20 Ind − CBT + PHA protocol
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Studies Patient characteristic Psychotherapy N Nsess I/G Medication N Combined
Schulberg (1996) Primary care IPT 93 16 Ind Nortriptyline 91 −
Scott (1992) Primary care CBT 29 16 Ind Amitriptyline 26 −
Counseling 29 16 Ind
Shamsaei (2008) Outpatients CBT 40 8 Ind Citalopram 40 CBT + citalopram
Sharp (2010) Postnatal depression Counseling 112 6 Ind Protocol 106 −
Sirey (2005) Elderly; outpatients − 5 Ind PHA (ns) 42 TIP + PHA (ns)
Sloane (1985) Elderly IPT 19 6 Ind Nortiptyline 10 −
Stravinsky (1994) Elderly; outpatients CBT 9 15 Grp − CBT + imipramine
Thompson (2001) Elderly CBT 31 18 Ind Desipramine 33 CBT + desipramine
Weissman (1979) Outpatients IPT 25 16 Ind Amitriptyline 24 IPT + Amitriptyline
Wiles (2008) Treatment resistant;
outpatients
− 16 Ind PHA (ns) 11 CBT + PHA (ns)
Williams (2000) Primary
care/dysthymia/elderly
PST 138 6 Ind Paroxetine 137 −
CBASP, cognitive behavioral analysis system of psychotherapy; CBT, cognitive behavior therapy; clomip, clomipramine; DBT, dialectic behavior
therapy; dysf., dysfuntion; Fluvox, ﬂuvoxetine; GP, general practitioner; Group ther, group therapy; GRP, group format; I/G, individual or group
format; I + P, combined individual and group format; Ind, individual format; IPT, interpersonal psychotherapy; Ns, not speciﬁed; Nsess, number of
sessions; Parox, paroxetine; PHA, pharmacotherapy; PST, problem-solving therapy; RET, rational emotive therapy; Setral, sertraline; SST, social
skills training; TCA, tricyclic antidepressant; TIP, Treatment Initiation Program.
aIf there was no response, a second-line antidepressant was substituted.
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